SANTA
CLARA, Calif., April 23,
2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq:
SMLR), a company that develops, manufactures and markets innovative
medical products and services that assist in evaluating and
treating chronic diseases, today announced that it will report
financial results for the first quarter ended March 31, 2024, after the close of U.S. financial
markets on Tuesday, May 7, 2024.
Doug Murphy-Chutorian, M.D., chief
executive officer of Semler Scientific, will host a conference call
at 4:30 pm ET the same day.
Renae Cormier, chief financial
officer, and Jennifer
Oliva-Herrington, chief operating officer, will join him on
the call.
We encourage participants to pre-register for the conference
call using the following link:
https://dpregister.com/sreg/10187645/fc081c8059.
Callers who pre-register will be given a conference passcode and
unique PIN to gain immediate access to the call and bypass the live
operator. Participants may pre-register at any time, including up
to and after the call start time.
Those without internet access or unable to pre-register may dial
in by calling:
Domestic callers: 833-816-1161
International callers: 412-317-0717
Please specify to the operator that you would like to join the
"Semler Scientific Call." The conference call will be archived on
Semler Scientific's website at www.semlerscientific.com.
About Semler Scientific, Inc.:
Semler Scientific,
Inc. develops, manufactures and markets innovative products and
services that assist in evaluating and treating chronic diseases.
Its flagship product, QuantaFlo®, which is patented and cleared by
the U.S. Food and Drug Administration (FDA), is a rapid
point-of-care test that measures arterial blood flow in the
extremities. The QuantaFlo test aids in the diagnosis of
cardiovascular diseases, such as peripheral arterial disease (PAD),
and Semler Scientific is seeking a new 510(k) clearance for
expanded indications. QuantaFlo is used by healthcare providers to
evaluate their patient's risk of mortality and major adverse
cardiovascular events (MACE). Semler Scientific has a minority
investment in Mellitus, SYNAPS Dx, as well as Monarch Medical
Technologies LLC, a privately held company whose product EndoTool®
offers a technological solution for inpatient glycemic management.
Additional information about Semler Scientific can be found at
www.semlerscientific.com.
CONTACT:
Renae Cormier, CFO
ir@semlerscientific.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/semler-scientific-to-report-first-quarter-financial-results-and-host-conference-call-on-may-7-2024-302124173.html
SOURCE Semler Scientific, Inc.